Avitide

Avitide is a private biotechnology company that has pioneered a next-generation, end-to-end affinity purification platform to address critical bioprocessing challenges in biologics manufacturing. Its core technology leverages extreme affinity ligand diversity to create highly specific, NaOH-regenerable purification resins for novel therapeutics, enabling partners to achieve significant improvements in process economics, development speed, and facility productivity. The company has built an ISO 9001:2015 certified modular manufacturing operation to ensure reliable, scalable GMP supply, positioning itself as a key enabler for the industrialization of advanced therapies like AAV-based gene therapies. Avitide's solutions aim to reduce the cost of goods and accelerate the development timelines for biopharmaceutical partners worldwide.

Proprietary end-to-end platform for discovering and developing highly specific, NaOH-regenerable affinity purification ligands (AVIPure™ resins) for a wide range of biopharmaceutical modalities, including AAV vectors, antibodies, vaccines, and cell-based therapies.

Avitide competes with large, established chromatography resin companies like Cytiva, Thermo Fisher Scientific, and Merck KGaA, which offer broad portfolios but may lack highly tailored solutions for novel modalities. It also faces competition from smaller biotech firms specializing in affinity ligands or purification technologies for specific areas like AAV. Avitide's differentiation lies in its platform approach to extreme ligand diversity and its focus on harsh-condition regenerable resins for commercial manufacturing.